vs
Side-by-side financial comparison of COLLEGIUM PHARMACEUTICAL, INC (COLL) and SITIME Corp (SITM). Click either name above to swap in a different company.
COLLEGIUM PHARMACEUTICAL, INC is the larger business by last-quarter revenue ($205.4M vs $113.6M, roughly 1.8× SITIME Corp). On growth, SITIME Corp posted the faster year-over-year revenue change (88.3% vs 12.9%). Over the past eight quarters, SITIME Corp's revenue compounded faster (60.9% CAGR vs 19.1%).
Collegium Pharmaceutical, Inc. is a specialty pharmaceutical firm focused on developing and commercializing innovative, abuse-deterrent pain management therapies. Operating primarily in the U.S. market, it offers extended-release analgesics for chronic pain patients, serving providers across primary and specialty care segments.
SiTime Corporation is a publicly traded fabless chipmaker based in Santa Clara, California that develops micro-electromechanical systems (MEMS), used for timing devices in electronics.
COLL vs SITM — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $205.4M | $113.6M |
| Net Profit | $17.0M | — |
| Gross Margin | 62.5% | 59.0% |
| Operating Margin | 29.6% | 30.2% |
| Net Margin | 8.3% | — |
| Revenue YoY | 12.9% | 88.3% |
| Net Profit YoY | 35.3% | — |
| EPS (diluted) | $0.48 | $-0.20 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $113.6M | ||
| Q4 25 | $205.4M | $113.3M | ||
| Q3 25 | $209.4M | $83.6M | ||
| Q2 25 | $188.0M | $69.5M | ||
| Q1 25 | $177.8M | $60.3M | ||
| Q4 24 | $181.9M | $68.1M | ||
| Q3 24 | $159.3M | $57.7M | ||
| Q2 24 | $145.3M | $43.9M |
| Q1 26 | — | — | ||
| Q4 25 | $17.0M | $9.2M | ||
| Q3 25 | $31.5M | $-8.0M | ||
| Q2 25 | $12.0M | $-20.2M | ||
| Q1 25 | $2.4M | $-23.9M | ||
| Q4 24 | $12.5M | $-18.8M | ||
| Q3 24 | $9.3M | $-19.3M | ||
| Q2 24 | $19.6M | $-26.8M |
| Q1 26 | — | 59.0% | ||
| Q4 25 | 62.5% | 56.4% | ||
| Q3 25 | 61.7% | 53.5% | ||
| Q2 25 | 57.7% | 51.9% | ||
| Q1 25 | 54.8% | 50.3% | ||
| Q4 24 | 54.0% | 52.6% | ||
| Q3 24 | 60.8% | 51.1% | ||
| Q2 24 | 62.5% | 49.1% |
| Q1 26 | — | 30.2% | ||
| Q4 25 | 29.6% | 1.6% | ||
| Q3 25 | 29.7% | -19.2% | ||
| Q2 25 | 18.7% | -35.4% | ||
| Q1 25 | 12.2% | -46.6% | ||
| Q4 24 | 20.9% | -33.8% | ||
| Q3 24 | 21.9% | -43.1% | ||
| Q2 24 | 32.7% | -73.7% |
| Q1 26 | — | — | ||
| Q4 25 | 8.3% | 8.1% | ||
| Q3 25 | 15.0% | -9.6% | ||
| Q2 25 | 6.4% | -29.0% | ||
| Q1 25 | 1.4% | -39.6% | ||
| Q4 24 | 6.9% | -27.6% | ||
| Q3 24 | 5.9% | -33.5% | ||
| Q2 24 | 13.5% | -61.0% |
| Q1 26 | — | $-0.20 | ||
| Q4 25 | $0.48 | $0.44 | ||
| Q3 25 | $0.84 | $-0.31 | ||
| Q2 25 | $0.34 | $-0.84 | ||
| Q1 25 | $0.07 | $-1.01 | ||
| Q4 24 | $0.36 | $-0.80 | ||
| Q3 24 | $0.27 | $-0.83 | ||
| Q2 24 | $0.52 | $-1.16 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $386.7M | $498.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $301.7M | $1.2B |
| Total Assets | $1.7B | $1.3B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $498.5M | ||
| Q4 25 | $386.7M | — | ||
| Q3 25 | $285.9M | — | ||
| Q2 25 | $222.2M | — | ||
| Q1 25 | $197.8M | — | ||
| Q4 24 | $162.8M | — | ||
| Q3 24 | $120.0M | — | ||
| Q2 24 | $271.6M | — |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $301.7M | $1.2B | ||
| Q3 25 | $274.8M | $1.1B | ||
| Q2 25 | $232.2M | $1.1B | ||
| Q1 25 | $234.4M | $692.5M | ||
| Q4 24 | $228.8M | $699.7M | ||
| Q3 24 | $234.3M | $696.2M | ||
| Q2 24 | $216.6M | $692.5M |
| Q1 26 | — | $1.3B | ||
| Q4 25 | $1.7B | $1.3B | ||
| Q3 25 | $1.6B | $1.3B | ||
| Q2 25 | $1.6B | $1.3B | ||
| Q1 25 | $1.6B | $872.1M | ||
| Q4 24 | $1.7B | $885.0M | ||
| Q3 24 | $1.6B | $877.9M | ||
| Q2 24 | $1.1B | $878.6M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $123.0M | — |
| Free Cash FlowOCF − Capex | $122.4M | — |
| FCF MarginFCF / Revenue | 59.6% | — |
| Capex IntensityCapex / Revenue | 0.3% | — |
| Cash ConversionOCF / Net Profit | 7.25× | — |
| TTM Free Cash FlowTrailing 4 quarters | $327.6M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $123.0M | $25.4M | ||
| Q3 25 | $78.4M | $31.4M | ||
| Q2 25 | $72.4M | $15.3M | ||
| Q1 25 | $55.4M | $15.0M | ||
| Q4 24 | $84.6M | $13.5M | ||
| Q3 24 | $-9.0M | $8.2M | ||
| Q2 24 | $67.4M | $-181.0K |
| Q1 26 | — | — | ||
| Q4 25 | $122.4M | $13.0M | ||
| Q3 25 | $78.3M | $26.3M | ||
| Q2 25 | $72.4M | $-2.9M | ||
| Q1 25 | $54.6M | $-1.3M | ||
| Q4 24 | $84.1M | $-2.4M | ||
| Q3 24 | $-9.2M | $-6.7M | ||
| Q2 24 | $67.1M | $-2.7M |
| Q1 26 | — | — | ||
| Q4 25 | 59.6% | 11.5% | ||
| Q3 25 | 37.4% | 31.5% | ||
| Q2 25 | 38.5% | -4.2% | ||
| Q1 25 | 30.7% | -2.1% | ||
| Q4 24 | 46.2% | -3.5% | ||
| Q3 24 | -5.8% | -11.6% | ||
| Q2 24 | 46.2% | -6.3% |
| Q1 26 | — | — | ||
| Q4 25 | 0.3% | 10.9% | ||
| Q3 25 | 0.1% | 6.1% | ||
| Q2 25 | 0.0% | 26.2% | ||
| Q1 25 | 0.4% | 27.0% | ||
| Q4 24 | 0.3% | 23.3% | ||
| Q3 24 | 0.2% | 25.7% | ||
| Q2 24 | 0.2% | 5.8% |
| Q1 26 | — | — | ||
| Q4 25 | 7.25× | 2.77× | ||
| Q3 25 | 2.49× | — | ||
| Q2 25 | 6.05× | — | ||
| Q1 25 | 22.92× | — | ||
| Q4 24 | 6.75× | — | ||
| Q3 24 | -0.96× | — | ||
| Q2 24 | 3.44× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
